MedTrace Logo

Simvastatin as a Treatment for Pulmonary Hypertension

NCT00180713 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to investigate the safety and efficacy of adding simvastatin to the current conventional treatment regimen for the management of pulmonary hypertension.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Simvastatin

Simvastatin 40mg od for 1 month, then 80mg od for 11 months

DRUG

Placebo

Placebo tablet once daily.

Sponsors & Collaborators

Principal Investigators

  • Martin Wilkins, MD FRCP · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-10-31
Completion
2009-05-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180713 on ClinicalTrials.gov